SCHEMBL888475

SCHEMBL888475

O=[N+]([O-])c1ccc(O)c([N+](=O)[O-])c1[N+](=O)[O-].[Hg]

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 4/20 0.64
TSHR P16473 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
CTSB P07858 3/20 0.52
TP53 P04637 2/20 0.52
HPGD P15428 2/20 0.52
CYP3A4 P08684 1/20 0.52
HIF1A Q16665 1/20 0.52
MAPK1 P28482 2/20 0.48
ALDH1A1 P00352 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAPT P10636 6/20 0.44
CASP6 P55212 2/20 0.44
POLB P06746 1/20 0.44
APEX1 P27695 1/20 0.44
ALDH5A1 P51649 1/20 0.44
ABAT P80404 1/20 0.44
CA12 O43570 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL145978 0.98 GPR35 (0.67) GPR35TSHRSMN1; SMN2CTSBTP53
SCHEMBL17512851 0.96 GPR35 (0.64) GPR35TSHRSMN1; SMN2CTSBTP53
Water SCHEMBL28180163 0.96 GPR35 (0.64) GPR35TSHRSMN1; SMN2CTSBTP53
Hydrochloric Acid SCHEMBL6372499 0.96 GPR35 (0.64) GPR35TSHRSMN1; SMN2CTSBTP53
SCHEMBL28638066 0.96 GPR35 (0.64) GPR35TSHRSMN1; SMN2CTSBTP53
SCHEMBL27270155 0.96 GPR35 (0.64) GPR35TSHRSMN1; SMN2CTSBTP53
Chloroform SCHEMBL28591707 0.90 GPR35 (0.58) GPR35TSHRSMN1; SMN2CTSBTP53
SCHEMBL10727444 0.88 GPR35 (0.85) GPR35TSHRSMN1; SMN2CTSBTP53
Naphthalene SCHEMBL28853785 0.88 GPR35 (0.61) GPR35TSHRSMN1; SMN2CTSBTP53
Phenol SCHEMBL28144767 0.87 GPR35 (0.59) GPR35TSHRSMN1; SMN2CTSBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1745156-A2 METHODS FOR DETECTING CHROMOSOME ABERRATIONS Dako Denmark A/S (DK) 2007-01-24 EP claimed
US-20060078904-A1 Methods for detecting chromosome aberrations DAKO DENMARK APS (DK) 2006-04-13 US claimed
WO-2005111235-A2 METHODS FOR DETECTING CHROMOSOME ABERRATIONS DAK DENMARK A/S (US) 2005-11-24 WO claimed
US-12291738-B2 Methods and/or use of oligonucleotide conjugates for assays and flow cytometry detections THE UNIVERSITY OF CHICAGO (US) 2025-05-06 US disclosed
CN-118159563-A Methods for enhanced BCMA immunohistochemical detection in human and monkey tissues 詹森生物科技公司 2024-06-07 CN disclosed
CN-115776987-A Barcoded exchangeable peptide-MHC multimer libraries 瑞佩尔托利免疫医药股份有限公司 2023-03-10 CN disclosed
US-20220170073-A1 METHODS AND/OR USE OF OLIGONUCLEOTIDE CONJUGATES FOR ASSAYS AND FLOW CYTOMETRY DETECTIONS THE UNIVERSITY OF CHICAGO (US) 2022-06-02 US disclosed
US-11029303-B2 PAH antibodies and uses thereof THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2021-06-08 US disclosed
EP-3733871-A1 COMPOSITIONS AND METHODS FOR DETECTION OF CHROMOSOMAL ABERRATIONS WITH NOVEL HYBRIDIZATION BUFFERS Dako Denmark A/S (DK) 2020-11-04 EP disclosed
EP-2636756-B2 COMPOSITIONS AND METHODS FOR DETECTION OF CHROMOSOMAL ABERRATIONS WITH NOVEL HYBRIDIZATION BUFFERS DAKO DENMARK AS (DK) 2019-11-20 EP disclosed
EP-2285982-B1 COMPOSITIONS AND METHODS FOR DETECTION OF CHROMOSOMAL ABERRATIONS WITH NOVEL HYBRIDIZATION BUFFERS DAKO DENMARK AS (DK) 2018-04-11 EP disclosed
WO-2008045819-A2 DETECTION AND IDENTIFICATION OF ORGANISMS VIA ANALYSIS OF NUCLEIC ACID SEQUENCES BIOVERIS CORPORATION (US) 2008-04-17 WO disclosed
US-7306916-B2 Methods for detecting chromosome aberrations DAKO DENMARK A/S (DK) 2007-12-11 US disclosed
EP-1751316-A2 NUCLEIC ACID PROBES AND NUCLEIC ACID ANALOG PROBES Dako Denmark A/S (DK) 2007-02-14 EP disclosed
EP-1745156-A2 METHODS FOR DETECTING CHROMOSOME ABERRATIONS Dako Denmark A/S (DK) 2007-01-24 EP disclosed
WO-2007005626-A1 COMPOSITIONS AND METHODS FOR DETECTING, AMPLIFYING, AND/OR ISOLATING NUCLEIC ACIDS BIOVERIS CORPORATION (US) 2007-01-11 WO disclosed
WO-2006117596-A2 NUCLEIC ACID PROBES AND NUCLEIC ACID ANALOG PROBES DAKO DENMARK A/S (US) 2006-11-09 WO disclosed
US-20060078904-A1 Methods for detecting chromosome aberrations DAKO DENMARK APS (DK) 2006-04-13 US disclosed
US-20050266459-A1 Nucleic acid probes and nucleic acid analog probes DAKOCYTOMATION DENMARK A/S (DK) 2005-12-01 US disclosed
WO-2005111235-A2 METHODS FOR DETECTING CHROMOSOME ABERRATIONS DAK DENMARK A/S (US) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11029303-B2 PAH antibodies and uses thereof PAH, AHR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 GPR35 751/4885TSHR 3293/4885SMN1; SMN2 4884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.